Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Receives Clearance to Sell miRNA Diagnostics in NY State

Premium

Rosetta Genomics said this week that it has obtained a clinical laboratory permit from the New York State Health Department, clearing the way for the company to market its three commercially available microRNA-based diagnostics in the state.

"We are pleased that these microRNA-based diagnostic products are now available to residents of all 50 US states including New York," Rosetta President and CEO Kenneth Berlin said in a statement.

The permit, Rosetta said, applies to miRview Meso, which is designed to differentiate lung cancer from mesothelioma; miRview Mets, which is meant to determine the source of cancers of unknown primary origin; and miRview Squamous, which aims to differentiate squamous from non-squamous non-small cell lung cancer.

The company said it is working to obtain NY approval for a second-generation version of miRview Mets.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.